Phase II study of subcutaneous daratumumab in combination with standard of care regimens for frontline and relapsed multiple myeloma
Latest Information Update: 24 May 2017
Price :
$35 *
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 24 May 2017 New trial record
- 17 May 2017 According to a Gemmab media release, this study is currently planned to start between the second half of 2017 and the first quarter of 2018.